PharmaTech US
Back to shop
Metabolic & Body CompositionResearch Use Only

Tirzepatide

15mg per vial

SKU: PT-TR15

Tirzepatide
Tirzepatide
Tirzepatide

$120

/ vial

Includes a 3ml bacteriostatic (BAC) water vial

Strength

Research Use Only. For research use only. Consult a licensed physician.

1

Overview

Unlike most items in this catalog, tirzepatide is an FDA-approved prescription drug (marketed as Mounjaro for diabetes and Zepbound for weight management). Dual agonism of GIP and GLP-1 receptors, improving insulin secretion, slowing gastric emptying, and reducing appetite.

Studied for

Described as research context — not a treatment claim.

Glycemic control, weight management, body composition — extensively studied given its approved-drug status.

Evidence & compliance note

Because it is an approved drug, this is the single highest compliance-risk SKU in the catalog. It draws more regulatory attention than any other item and is a candidate for a specific legal-review pass before launch.

Preparation & storage

Lyophilized. Reconstitute with bacteriostatic water per the general reference below.

General reconstitution & storage reference for lyophilized peptides:

  1. 1Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water — the preservative meaningfully extends usable shelf life.
  2. 2In bacteriostatic water, refrigerate at 2–8°C, typically usable for ~28–30 days. In plain sterile water (no preservative): 7–14 days.
  3. 3Lyophilized (unmixed) vials are stable at refrigerated or, for some peptides, frozen temperatures for extended periods prior to reconstitution.
  4. 4Avoid repeated freeze-thaw cycles, direct light/UV exposure, and heat — these are the primary drivers of peptide degradation.
  5. 5Reconstitute gently: inject the water down the inside wall of the vial and swirl — don't shake, which can denature the peptide structure.
Preparation video — coming in a later phase.

Precautions

GI side effects common; carries the same GLP-1-class thyroid C-cell tumor caution seen on approved labeling. The FDA's 2025 compounding crackdown (removal from the drug shortage list) specifically increased enforcement attention on non-pharmacy tirzepatide sales.

Sources

Related research compounds